13.62
price down icon1.52%   -0.21
after-market Handel nachbörslich: 13.62
loading
Schlusskurs vom Vortag:
$13.83
Offen:
$14.03
24-Stunden-Volumen:
91,660
Relative Volume:
1.01
Marktkapitalisierung:
$199.19M
Einnahmen:
$1.80M
Nettoeinkommen (Verlust:
$-241.36M
KGV:
-3.363
EPS:
-4.05
Netto-Cashflow:
$-197.90M
1W Leistung:
-14.88%
1M Leistung:
-14.88%
6M Leistung:
-60.75%
1J Leistung:
-38.90%
1-Tages-Spanne:
Value
$13.52
$14.05
1-Wochen-Bereich:
Value
$12.25
$17.41
52-Wochen-Spanne:
Value
$10.80
$39.79

Inhibrx Biosciences Inc Stock (INBX) Company Profile

Name
Firmenname
Inhibrx Biosciences Inc
Name
Telefon
(858) 795-4220
Name
Adresse
11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA
Name
Mitarbeiter
0
Name
Twitter
Name
Nächster Verdiensttermin
2024-05-24
Name
Neueste SEC-Einreichungen
Name
INBX's Discussions on Twitter

Vergleichen Sie INBX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
INBX 13.62 199.19M 1.80M -241.36M -197.90M -4.05
VRTX 467.01 119.87B 10.63B -479.80M -1.35B 13.33
REGN 762.00 83.27B 13.85B 4.65B 3.32B 35.06
ARGX 567.90 33.96B 1.86B -40.29M -1.28B -4.16
ALNY 232.27 30.18B 2.09B -332.26M 16.06M -4.14
BNTX 101.87 24.42B 3.30B -501.07M 1.03B 11.54

Inhibrx Biosciences Inc Stock (INBX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-01-23 Herabstufung JMP Securities Mkt Outperform → Mkt Perform
2022-03-16 Eingeleitet SMBC Nikko Outperform
2021-09-21 Eingeleitet JMP Securities Mkt Outperform
2021-04-26 Fortgesetzt Credit Suisse Outperform
2020-09-14 Eingeleitet Credit Suisse Outperform
2020-09-14 Eingeleitet Evercore ISI Outperform
Alle ansehen

Inhibrx Biosciences Inc Aktie (INBX) Neueste Nachrichten

pulisher
03:58 AM

Trend Tracker for (INBX) - Stock Traders Daily

03:58 AM
pulisher
Nov 17, 2024

The recent drop in prices must have disappointed Inhibrx Biosciences, Inc. (NASDAQ:INBX) institutional investors who own 43% of the shares - Yahoo Finance

Nov 17, 2024
pulisher
Nov 17, 2024

institutional investors of Inhibrx Biosciences, Inc. (NASDAQ:INBX) must be disappointed after last week's 15% drop - Simply Wall St

Nov 17, 2024
pulisher
Nov 15, 2024

Perceptive Advisors LLC Bolsters Stake in Inhibrx Biosciences Inc - GuruFocus.com

Nov 15, 2024
pulisher
Nov 14, 2024

Inhibrx Biosciences Inc (INBX) Quarterly 10-Q Report - Quartz

Nov 14, 2024
pulisher
Nov 14, 2024

Inhibrx Q3 Loss Narrows to $2.84/Share, Maintains $196M Cash for Clinical Programs | INBX Stock News - StockTitan

Nov 14, 2024
pulisher
Nov 12, 2024

Inhibrx Biosciences Inc. (INBX) Quarterly 10-Q Report - Quartz

Nov 12, 2024
pulisher
Nov 09, 2024

Wilson Sonsini Knocks Out Claims Against Inhibrx Biosciences in Trade Secrets Verdict - Law.com

Nov 09, 2024
pulisher
Nov 08, 2024

Inhibrx Biosciences’ Trade Secret Case - Global Legal Chronicle

Nov 08, 2024
pulisher
Nov 07, 2024

(INBX) Trading Signals - Stock Traders Daily

Nov 07, 2024
pulisher
Nov 05, 2024

Inhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique Platform - Seeking Alpha

Nov 05, 2024
pulisher
Nov 04, 2024

Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation - Financial Times

Nov 04, 2024
pulisher
Oct 25, 2024

James Sabry on industry-shaping changes in innovation and deal-making - BioCentury

Oct 25, 2024
pulisher
Oct 06, 2024

Long Term Trading Analysis for (INBX) - Stock Traders Daily

Oct 06, 2024
pulisher
Oct 01, 2024

Inhibrx Biosciences' SWOT analysis: cash-rich biotech stock faces pivotal year - Investing.com Australia

Oct 01, 2024
pulisher
Sep 30, 2024

Inhibrx Biosciences' SWOT analysis: cash-rich biotech stock faces pivotal year By Investing.com - Investing.com South Africa

Sep 30, 2024
pulisher
Sep 25, 2024

How To Trade (INBX) - Stock Traders Daily

Sep 25, 2024
pulisher
Sep 19, 2024

why ImmunityBio Inc [IBRX] is a Good Choice for Investors After New Price Target of $6.38 - The DBT News

Sep 19, 2024
pulisher
Sep 19, 2024

INVX underperforms with a -2.86 decrease in share price - US Post News

Sep 19, 2024
pulisher
Sep 19, 2024

You might want to take a look at Imunon Inc (IMNN) now - SETE News

Sep 19, 2024
pulisher
Sep 19, 2024

Immuneering Corp [IMRX] Shares Fall Approximately -71.25% Over the Year - Knox Daily

Sep 19, 2024
pulisher
Sep 19, 2024

ImmunityBio, Inc. (NASDAQ:IBRX) Shares Purchased by Private Advisor Group LLC - Defense World

Sep 19, 2024
pulisher
Sep 19, 2024

Incyte (NASDAQ:INCY) Given “Hold” Rating at Truist Financial - Defense World

Sep 19, 2024
pulisher
Sep 19, 2024

Inhibrx, Inc. (NASDAQ:INBX) Short Interest Down 6.9% in August - Defense World

Sep 19, 2024
pulisher
Sep 18, 2024

InnovAge (NASDAQ:INNV) Trading Up 4.2% - Defense World

Sep 18, 2024
pulisher
Sep 18, 2024

William Hoffman Sells 40,000 Shares of Inari Medical, Inc. (NASDAQ:NARI) Stock - Defense World

Sep 18, 2024
pulisher
Sep 18, 2024

INmune Bio, Inc. (NASDAQ:INMB) Sees Large Increase in Short Interest - Defense World

Sep 18, 2024
pulisher
Sep 18, 2024

INmune Bio stock remains a Buy with positive data correlation in Alzheimer’s study, says Scotiabank - Investing.com

Sep 18, 2024
pulisher
Sep 18, 2024

A review of IMNN’s current quarter earnings predictions - US Post News

Sep 18, 2024
pulisher
Sep 18, 2024

Its Stock Has Paid Off Big Time For INmune Bio Inc - SETE News

Sep 18, 2024
pulisher
Sep 18, 2024

Inhibrx, Inc. (NASDAQ:INBX) Short Interest Update - MarketBeat

Sep 18, 2024
pulisher
Sep 18, 2024

IBRX Stock on the Rise: A Promising Investment - The InvestChronicle

Sep 18, 2024
pulisher
Sep 18, 2024

Market Watch: Immuneering Corp (IMRX)’s Noteworthy Drop, Closing at 2.78 - The Dwinnex

Sep 18, 2024
pulisher
Sep 18, 2024

Truist downgrades Incyte to "hold" on doubts of near-term prospects - XM

Sep 18, 2024
pulisher
Sep 18, 2024

Incyte (NASDAQ:INCY) Receives Market Perform Rating from JMP Securities - Defense World

Sep 18, 2024
pulisher
Sep 18, 2024

Imunon (NASDAQ:IMNN) Shares Up 5.6% - Defense World

Sep 18, 2024
pulisher
Sep 17, 2024

Ratio Review: Analyzing Innovex International Inc. (INVX)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Sep 17, 2024
pulisher
Sep 17, 2024

10% Owner Of Impinj Makes $20.00M Buy - Benzinga

Sep 17, 2024
pulisher
Sep 16, 2024

Inmune Bio CFO acquires $49k in company stock By Investing.com - Investing.com Canada

Sep 16, 2024
pulisher
Sep 16, 2024

Inmune Bio CEO acquires $98k in company stock - Investing.com

Sep 16, 2024
pulisher
Sep 16, 2024

Inmune Bio CFO buys $49k in company stock - Investing.com

Sep 16, 2024
pulisher
Sep 16, 2024

Inhibrx CEO buys shares worth over $629k - Investing.com India

Sep 16, 2024
pulisher
Sep 16, 2024

Inhibrx CEO buys shares worth over $629k By Investing.com - Investing.com Canada

Sep 16, 2024
pulisher
Sep 16, 2024

Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch

Sep 16, 2024
pulisher
Sep 16, 2024

How will ImmunityBio Inc’s (IBRX) earnings compare to estimates this quarter? - US Post News

Sep 16, 2024
pulisher
Sep 16, 2024

What is IMRX’s price-to-sales ratio telling us about the company’s value? - US Post News

Sep 16, 2024
pulisher
Sep 16, 2024

Impinj 10% Owner Trades $20.00M In Company Stock - Benzinga

Sep 16, 2024
pulisher
Sep 16, 2024

Take off with ImmunityBio Inc (IBRX): Get ready for trading - SETE News

Sep 16, 2024
pulisher
Sep 16, 2024

SEC Form 424B5 filed by INmune Bio Inc. - Quantisnow

Sep 16, 2024
pulisher
Sep 16, 2024

Financial Metrics Check: ImmunityBio Inc (IBRX)’s Ratios for Trailing Twelve Months - The Dwinnex

Sep 16, 2024
pulisher
Sep 16, 2024

IMRX Stock Soars on Upbeat Efficacy Data From Pancreatic Cancer Study - Yahoo Finance

Sep 16, 2024

Finanzdaten der Inhibrx Biosciences Inc-Aktie (INBX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$18.98
price up icon 3.66%
$76.97
price up icon 1.45%
$39.51
price up icon 7.22%
$359.21
price down icon 1.11%
$187.69
price down icon 0.81%
$101.87
price up icon 2.16%
Kapitalisierung:     |  Volumen (24h):